Results 171 to 180 of about 87,574 (284)

Benefits and challenges in everyday life for patients performing subcutaneous immunoglobulin treatment at home: a qualitative interview study. [PDF]

BMJ Open
Johansen MB, Kass ED, Christensen J.
europepmc   +1 more source

Standardized Tapering off Subcutaneous Immunoglobulin in Chronic Inflammatory Demyelinating Polyneuropathy. [PDF]

J Neuromuscul Dis, 2023
Markvardsen LK, Sindrup SH, Christiansen I, Sheikh AM, Holbech JV, Andersen H.   +5 more
europepmc   +1 more source

Active Immunization of the Dam [PDF]

, 1984
Bachmann, Peter A., Eichhorn, Werner, Heß, R. Günther   +2 more
core   +1 more source

Changes of Subcutaneous Tissue Echogenicity During Facilitated Subcutaneous Immunoglobulin Application [PDF]

Journal of Allergy and Clinical Immunology, 2020
Milos Jesenak, Marek Pršo, Marek Kozar, Peter Banovcin   +3 more
openaire   +1 more source

Clinical Significance of Copper Chaperone for Superoxide Dismutase in Colorectal Cancer

Annals of Gastroenterological Surgery, EarlyView.
ABSTRACT Background Targeting Cu transport proteins is an innovative therapeutic approach for combating cancer. However, the mechanisms underlying the malignant potential of Cu transport proteins remain largely unknown. To address this issue, we focused on the oncogenic potential of copper chaperones for superoxide dismutase (CCS) in colorectal cancer (
Nobuo Takiguchi, Mamoru Uemura, Mao Osaki, Chikako Kusunoki, Masakatsu Paku, Mitsunobu Takeda, Yuki Sekido, Tsuyoshi Hata, Atsushi Hamabe, Takayuki Ogino, Norikatsu Miyoshi, Mitsuyoshi Tei, Yoshinori Kagawa, Hirofumi Yamamoto, Yuichiro Doki, Hidetoshi Eguchi   +15 more
wiley   +1 more source

Correction: Transitioning subcutaneous immunoglobulin 20% therapies in patients with primary and secondary immunodeficiencies: Canadian real‑world study. [PDF]

Allergy Asthma Clin Immunol, 2023
Keith PK, Cowan J, Kanani A, Kim H, Lacuesta G, Lee JK, Chen J, Park M, Gladiator A.   +8 more
europepmc   +1 more source

Natural Killer Cells in Cancer Immunotherapy [PDF]

, 2019
Arndt MA, Chester C, Cortez VS, D'Andrea A, Elsasser D, Ferrini S, Gao Y, Hartmann F, Lotze MT, Miller JS, Orr MT, Seillet C, Soiffer RJ, Soto EO, Weiner LM, Yron I   +15 more
core   +1 more source

2026 Update on the Management of Diffuse Large B‐Cell Lymphoma

American Journal of Hematology, EarlyView.
ABSTRACT Diffuse large B‐cell lymphoma (DLBCL) is the most common type of NHL in the Western Hemisphere. It comprises a heterogenous group of lymphomas, with different biology and clinical prognoses. R‐CHP remains the backbone of therapy, and frontline therapeutic options in fit patients are pola‐R‐CHP and R‐CHOP, whereas elderly or frail/unfit ...
Elise A. Chong, Emily B. Tomasulo, Stefan K. Barta   +2 more
wiley   +1 more source

Early and Sustained Improvements in Sense of Smell With Tezepelumab Treatment in Patients With Chronic Rhinosinusitis With Nasal Polyps (WAYPOINT)

International Forum of Allergy &Rhinology, EarlyView.
ABSTRACT Background Loss of smell is a principal symptom of chronic rhinosinusitis with nasal polyps (CRSwNP), affecting health‐related quality of life and posing a safety hazard. Methods WAYPOINT (NCT04851964), a phase 3, multicenter trial in adults with uncontrolled CRSwNP, randomized patients 1:1 to receive tezepelumab 210 mg or placebo ...
Joaquim Mullol, Joseph K. Han, Tanya M. Laidlaw, Claire Hopkins, Anju T. Peters, Oliver Pfaar, Martin Desrosiers, Stella E. Lee, Andrew P. Lane, Claudia Chen, Yun Chon, Sandhia S. Ponnarambil, Andrew Foster, Andrew W. Lindsley, Christopher S. Ambrose   +14 more
wiley   +1 more source

Usefulness of subcutaneous immunoglobulin therapy in the management of myasthenia gravis: a retrospective cohort study. [PDF]

J Neurol, 2022
Barnay M, Duval F, Solé G, Carla L, Mathis S, Le Masson G.   +5 more
europepmc   +1 more source